| Literature DB >> 30930813 |
Omid V Ebrahimi1, Ståle Pallesen1, Robin M F Kenter1,2, Tine Nordgreen1,2.
Abstract
Background: Fear of Public Speaking (FoPS) or public speaking anxiety is a type of social anxiety and the single most commonly feared situation in the population. FoPS is disabling with negative occupational, academic, and social consequences, reported by up to one third of the population. FoPS in adolescence and adulthood is associated with an increased risk of developing generalized social anxiety disorder with further impairments. Since the last review on FoPS, a significant number of randomized controlled trials (RCTs) have been conducted assessing the effects of novel interventions with innovative modes of delivery.Entities:
Keywords: fear of public speaking; meta-analysis; psychological treatment; public speaking anxiety; randomized controlled trial; social anxiety disorder; systematic review
Year: 2019 PMID: 30930813 PMCID: PMC6428748 DOI: 10.3389/fpsyg.2019.00488
Source DB: PubMed Journal: Front Psychol ISSN: 1664-1078
Figure 1PRISMA flow diagram of the study selection process.
Selected characteristics of the included randomized controlled trials assessing the effects of psychological treatments on fear of public speaking and generalized social anxiety.
| Anderson et al., | D | VRET | 30 | 8 | VR | Individual | FTF | C/B | PRCS | BFNE | 72 |
| EGT | 39 | 8 | Group | FTF | C/B | Speech length | |||||
| WL | 28 | Speech length-Peak anxiety | |||||||||
| Ayres, | ND | Vis. | 20 | 1 | Imaginary | Individual | FTF | PD | PRCA | None | None |
| Active vis. | 20 | 1 | Imaginary | Individual | FTF | PD | BASA | ||||
| Active vis. + | 20 | 1 | Imaginary | Individual | FTF | PD | |||||
| vis. | |||||||||||
| WL | 20 | ||||||||||
| Placebo | 20 | ||||||||||
| Ayres et al., | ND | Performance | 20 | 1 | Imaginary | Individual | FTF | PD | PRCA | None | None |
| Vis. | BASA | ||||||||||
| Placebo | 19 | ||||||||||
| WL | 20 | 1 | |||||||||
| Botella et al., | D | SA-CBT | 30 | N/A | Video | Self-help | Int. delivered | C/B | FPSQ | BFNE | 12 |
| CBT | 22 | 16 | Video | Individual | FTF | C/B | SSPS-P | SAD | |||
| WL | 25 | SSPS-N | |||||||||
| IST-P | |||||||||||
| IST-T | |||||||||||
| Cunningham et al., | ND | TLM | 17 | 3.3 | None | Individual | Telephone | Other | PRCS | None | None |
| WL | 19 | SRP-F | |||||||||
| SRP-A | |||||||||||
| Deffenbacher et al., | ND | Hom. AMT | 13 | 6 | Imaginary | Group | FTF | C/B | PRCS | None | 12 |
| Het. AMT | 12 | 6 | Imaginary | Group | FTF | C/B | TAS | ||||
| NT | 16 | ||||||||||
| Foley and Spates, | ND | EMDR | 9 | NR | Imaginary | Individual | FTF | EMDR | BASA | None | NR |
| EMDR | 9 | NR | Imaginary | Individual | FTF | EMDR | HR-R | ||||
| w/sound | |||||||||||
| EMDR | 9 | NR | Imaginary | Individual | FTF | EMDR | |||||
| w/resting eyes | |||||||||||
| NT | 9 | ||||||||||
| Fremouw and Harmatz, | ND | Latent helpers | 10 | 10 | Group | FTF | C/B | GRSA | SAD | 3 | |
| Helpers | 10 | 10 | Group | FTF | C/B | PRCS | FNE | ||||
| Helpees | 10 | 5 | Group | FTF | C/B | AD | |||||
| WL | TBCL | ||||||||||
| OA | |||||||||||
| Fremouw and Zitter, | ND | Skills training | 12 | 5 | Imaginary | Group | FTF | C/B | PRCS | SAD | 2 |
| Cogn. | 12 | 5 | Group | FTF | C/B | AD | |||||
| relaxation | BASA | ||||||||||
| Placebo | 11 | OA | |||||||||
| WL | 11 | ToS | |||||||||
| Gallego et al., | D | SA-CBT | 13 | N/A | Video | Self-help | Int. delivered | C/B | PRCS | BFNE | None |
| WL | 11 | SSPS-P | SAD | ||||||||
| SSPS-N | |||||||||||
| IST-P | |||||||||||
| IST-T | |||||||||||
| IST-O | |||||||||||
| Gatchel and Proctor, | ND | Biofeedback | 18 | 3 | Imaginary | Individual | FTF | C/B | USRA | None | 1 |
| Placebo | 18 | TBCL | |||||||||
| HR | |||||||||||
| Goldfried and Trier, | ND | Self-control | 10 | 5 | Imaginary | Group | FTF | C/B | TBCL | SAD | 1.5 |
| relaxation | Silence | FNE | |||||||||
| Standard | 9 | 5 | Imaginary | Group | FTF | C/B | AD | ||||
| Relaxation | SAS | ||||||||||
| Placebo | 8 | PRCS | |||||||||
| S-R | |||||||||||
| Inventory | |||||||||||
| TAS | |||||||||||
| Gross and Fremouw, | ND | Cog. | 23 | 4 | NR | NR | FTF | C/B | SAS | FNE | None |
| Restructuring | PRCS | SAD | |||||||||
| Progressive | 26 | 4 | NR | NR | FTF | C/B | HR | ||||
| relaxation | SCL | ||||||||||
| WL | 10 | TBCL | |||||||||
| OA | |||||||||||
| Harris et al., | ND | VRT | 8 | 4 | VR | Individual | FTF | C/B | PRCS | LSAS | None |
| WL | 6 | STAI | |||||||||
| ATPS | |||||||||||
| HR | |||||||||||
| Hayes and Marshall, | ND | SIT | 14 | 8 | Imaginary | Group | FTF | C/B | SUDS | SAD | 6 |
| SIT + Flooding | 14 | 8 | Mix | Group | FTF | C/B | FT | FNE | |||
| SIT + flooding | 14 | 8 | Mix | Group | FTF | C/B | |||||
| + skills | |||||||||||
| training | |||||||||||
| Placebo | 14 | ||||||||||
| Hekmat et al., | ND | Instructional | 10 | 3 | Imaginary | Individual | FTF | C/B | S-R | None | 1 |
| desem. | Inventory | ||||||||||
| Placebo | 10 | ACL | |||||||||
| WL | 10 | PRCS | |||||||||
| TBCL | |||||||||||
| Homer et al., | ND | EMDR | 17 | 1 | Imaginary | Individual | FTF | C/B | PRCS | None | None |
| Placebo | 19 | 1 | Imaginary | Individual | FTF | C/B | SA | ||||
| Johnson et al., | ND | Group desen. | 8 | 9 | Imaginary | Group | FTF | C/B | PRCS | None | None |
| Speech | 8 | 9 | Group | FTF | C/B | ||||||
| practice | |||||||||||
| NT | 10 | ||||||||||
| Karst and Trexler, | ND | Fixed-role | 8 | 3 | None | Group | FTF | C/B | PRCS | SFS | N/A |
| therapy | |||||||||||
| RET | 8 | 3 | None | Group | FTF | C/B | AS | SFS | |||
| NT | 6 | ||||||||||
| Kirsch and Henry, | ND | Systematic desen. | 11 | 5 | Imaginary | Individual | FTF | C/B | None | None | |
| Operant desen. | 11 | 5 | Imaginary | Individual | FTF | C/B | TBCL | ||||
| Placebo | 11 | ||||||||||
| Marshall et al., | ND | TA desensitization | 9 | 5 | Imaginary | Group | FTF | C/B | TBCL | None | None |
| SA desensitization | 6 | N/A | Imaginary | Self-help | SHM | C/B | SUDS | ||||
| SA desen. + check | 9 | 5 | Imaginary | Self-help | SHM | C/B | |||||
| SA desen. + placebo | 9 | 5 | Imaginary | Group | FTF | C/B | |||||
| Placebo | 9 | ||||||||||
| NT | 9 | ||||||||||
| McNally et al., | ND | ABM | 7 | 4 | None | Individual | Computerized | C/B | PRCS | LSAS | None |
| I-ABM | 7 | 4 | None | Individual | Computerized | C/B | USRA-B | ||||
| Placebo | 7 | USRA-A | |||||||||
| SPRS | |||||||||||
| HR-B | |||||||||||
| HR-A | |||||||||||
| SysB | |||||||||||
| SysA | |||||||||||
| DiaB | |||||||||||
| DiaA | |||||||||||
| Meichenbaum et al., | ND | Desensitization | 11 | 8 | Group | FTF | C/B | PRCS | SAD | 3 | |
| Insight | 11 | 8 | Imaginary | Group | FTF | Gestalt | ACL | FNE | |||
| Des. + insight | 10 | 8 | Group | FTF | Gestalt | AD | |||||
| Placebo | 10 | TBCL | |||||||||
| WL | 7 | Word count | |||||||||
| Silence | |||||||||||
| Ah-statements | |||||||||||
| Newman et al., | D | Exposure only | 16 | 8 | Mix | Group | FTF | C/B | SAS | SPAI | None |
| WL | 17 | TAS | SAD | ||||||||
| PRCS | FNE | ||||||||||
| GST | |||||||||||
| Osberg, | ND | Applied relaxation | 15 | 6 | Mix | Group | FTF | C/B | SAD | 1 | |
| Standard relaxation | 13 | 6 | Imaginary | Group | FTF | C/B | |||||
| Speech practice | 15 | 6 | Mix | Group | FTF | C/B | |||||
| WL | 14 | ||||||||||
| Schoenberger et al., | CBT | 17 | 5 | Group | FTF | C/B | AE | FNE | None | ||
| CBT | 15 | 5 | Group | FTF | C/B | PRCS | |||||
| w/hypnosis | SUDS | ||||||||||
| WL | 10 | TBCL | |||||||||
| PR | |||||||||||
| Schwartz and Kaloupek, | ND | Exercise and exposure | 13 | 4 | Imaginary | Individual | FTF | C/B | None | None | |
| Exposure alone | 13 | 4 | Imaginary | Individual | FTF | C/B | |||||
| Exercise alone | 13 | 4 | None | Individual | FTF | Other | Silence | ||||
| Placebo | 13 | 4 | Prepatory HR | ||||||||
| Speech HR | |||||||||||
| Prepatory SCL | |||||||||||
| Speech SCL | |||||||||||
| Prepatory SCR | |||||||||||
| Speech SCR | |||||||||||
| Spector et al., | ND | CCR-W | 9 | 6 | None | NR | FTF | C/B | PRCS | FNE | 2 |
| CCR-A | 8 | 6 | None | NR | FTF | C/B | S-R | ||||
| Placebo | 7 | Inventory | |||||||||
| WL | 8 | BRS | |||||||||
| Trussell, | ND | GBR/F | 15 | 8 | Group | FTF | C/B | PRCS | None | 1.5 | |
| GBR/F + systematic des. | 15 | 8 | Imaginary | Group | FTF | C/B | |||||
| NT | 13 | BASA | |||||||||
| Wallach et al., | ND | VRCBT | 28 | 12 | VR | Individual | FTF | C/B | SSPS-P | FNE | 12 |
| CBT | 30 | 12 | Imaginary | Individual | FTF | C/B | SSPS-N | LSAS-Fear | |||
| WL | 30 | OR | LSAS-Avoid. | ||||||||
| SRA |
ABM, Attention Bias Modification; ACL, Affect adjective Checklist; AD, Anxiety Differential; AE, Anxiety Expectancy; AS, Anxiety Scale with 10 points similar to Fear Thermometer; ATPS, Attitudes Toward Public Speaking; BASA, Behavioral Assessment of Speech Anxiety; BFNE, Brief Fear of Negative Evaluation; BRS, Behavior Rating System; CBT, Cognitive Behavioral Therapy; CCR-W, Cue-Controlled Relaxation - Word Cue; CCR-A, Cue-Controlled Relaxation – Aroma Cue; C/B, Intervention belonging to the Cognitive or Behavioral family; D, Diagnostic; DiaA, Diastolic blood pressure after speaking; DiaB, Diastolic blood pressure before speaking; EGT, Exposure Group Therapy; EMDR, Eye Movement Desensitization and Reprocessing; FNE, Fear of Negative Evaluation; FT, Fear Thermometer; FTF, Face to face; FU, Follow-Up in months; GBR/F, Graduated Behavior Rehearsal/Feedback; GR, Global Rating of anxiety; GRSA, General Rating of Speech Anxiety; GST, Graded Speech Task; Het. AMT, Heterogeneous Anxiety Management Training; Hom. AMT, Homogenous Anxiety Management Training; HR, Heart Rate; HR-A, Heart Rate After speaking; HR-B, Heart-Rate Before speaking; HR-R, Heart Rate Reactivity; Instr., instrument; Int. delivered, Internet-delivered therapy; IST-P, Impromptu Speech Task – Patient reported; IST-T, Impromptu Speech Task – Therapist reported; IST-O, Impromptu Speech Task—Observer reported; I-ABM, Inverse Attention Bias Modification; LSAS, Liebowitz Social Anxiety Scale; Mix, Mixture of in vivo and imaginary exposure; N/A, Not available; ND, Non-diagnostic; NR, Not Reported; NT, No Treatment control group; OA, Overall Anxiety; OR, Observer Rating of anxiety during behavioral task; PD, Psychodynamic; Pop., Population; PR, Pulse Rate; PRCA, Personal Report of Communication Apprehension; PRCS, Personal Report of Confidence as Speaker; RET, Rational-Emotive Therapy; SA, State Anxiety on a visual analog scale; SAD, Social Avoidance and Distress scale; SAS, State Anxiety Scale; SCL, Skin Conductance Level; SCR, Skin Conductance Response; SFS, Social Fear Scale; SHM, Self-Help Material; STAI, State-Trait Anxiety Inventory; SPAI, Social Phobia and Anxiety Inventory; SPRS, Social Performance Rating Scale; SUDS, Subjective Units of Discomfort Scale; SysA, Systolic blood pressure after speaking; SysB, Systolic blood pressure before speaking; SA-CBT, Self-administered CBT; SRA, Self-Rated measure of Anxiety during behavioral task; SRP-A, Self-Rated Performance – Anxiety; SRP-F, Self-Rated Performance—Fear; S-R Inventory, S-R Inventory of speech anxiousness; TA, Therapist-administered; TAS, Trait Anxiety Scale; TBCL, Timed Behavior Checklist; TLM, The Lefkoe Method; ToS, Time of Silence; USRA, Unspecified Self-Report measure of Anxiety; USRA-A, Unspecified Self-Report measure of Anxiety After speaking; USRA-B, Unspecified Self-Report measure of Anxiety Before speaking; Vis., Visualization; VR, Virtual Reality; VRCBT, Virtual Reality Cognitive Behavioral Therapy; VRET, Virtual Reality Exposure Therapy; WL, Waitlist control.
The PRCA was only used when the study reported the results based on its public speaking subscale alone.
Physiological outcome measures.
Behavioral outcome measure assessing overt signs of anxiety.
Study authors only provided the mean number of sessions for all participants, with a range of 2–5 sessions.
The follow-up results of this study were described qualitatively. No quantitative data were available here.
The authors included these measures but did not report their outcomes.
Reported in separate follow-up paper.
Figure 2Estimated risk of bias of the included studies. SR, Self-report.
Figure 3A forest plot of the standardized effect sizes of psychological treatments for fear of public speaking compared with control conditions.
Figure 4A forest plot of the standardized effect sizes of psychological treatments aimed at FoPS for generalized social anxiety compared with control conditions.
Figure 5A forest plot of the standardized effect sizes of psychological treatments aimed at fear of public speaking at follow-up.
Figure 6A forest plot of the standardized effect sizes of psychological treatments aimed at fear of public speaking on generalized social anxiety at follow-up.
Multivariate meta-regression analyses of the four overall effect sizes calculated in this study, with standard regression coefficients and their associated 95% CI and p-value are provided.
| Theoretical framework | C/B (50) | 0.673 | Ref.0.369 | 0.068 to 0.671 | 0.016 | |||
| Type of control group | Placebo (33) | 0.649 | Ref.0.315 | 0.068 to 0.563 | 0.012 | |||
| Percentage of measures other than self-report (continuous) | −0.010 | −0.015 to −0.005 | 0.000 | |||||
| Technology-delivered vs. non-technological interventions | Non-tech. (55) | 0.753 | Ref.0.043 | −0.315 to 0.401 | 0.814 | |||
| Follow-up length (continuous) | −0.003 | −0.015 to 0.007 | 0.509 | |||||
| Type of effect size at follow-up | Between (8) | 0.791 | Ref. | −0.028 to 0.988 | 0.064 | |||
| Intercept | 0.862 | 0.612 to 1.106 | 0.000 | 0.792 | 0.369 to 1.214 | 0.000 | ||
Between, Between group comparison of intervention vs. control group; CI, Confidence Interval of regression coefficient; Coeff., regression coefficient; C/B, Cognitive or Behavioral; FoPS, Fear of public speaking; g = Hedges' g; k = number of interventions; Non-tech, Non-technological intervention; Ref., Reference group; Tech. Technological intervention; Within, Within group comparison between based on pre-intervention vs. follow-up assessment; WL/NT, Waiting list control group or No-Treatment control group.
Figure 7A forest plot of the change in efficacy from post-treatment to follow-up of psychological treatments aimed at fear of public speaking.
Figure 8A forest plot of the change in efficacy from post-treatment to follow-up of psychological treatments aimed at fear of public speaking on generalized social anxiety.